Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
April 7, 2014
Blueprint Medicines Presents Positive Data on First Selective FGFR4 Inhibitor
Download … [Read More...]
March 24, 2014
Blueprint Medicines to Present on the First Isoform Selective FGFR4 Inhibitor at the AACR … [Read More...]